PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events
- 1 June 1997
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 78 (01) , 656-660
- https://doi.org/10.1055/s-0038-1657607
Abstract
Circulating (PAI-1) levels are elevated in patients with coronary heart disease and may play an important role in the development of atherothrombosis. Many clinical studies have indicated that the insulin resistance syndrome, which is a situation predisposing to diabetes and ischemic heart disease, may be a major regulator of PAI-1 expression, especially in determining plasma PAI-1 levels. Central obesity is a characteristic of insulin resistance and is a well recognized risk factor for coronary heart disease. Recently the production of PAI-1 by adipose tissue, in particular by tissue from omentum, has been demonstrated and could be an important contributor to the elevated plasma PAI-1 levels observed in insulin resistant patients. Besides the effect of the metabolic status on plasma PAI-1 levels, the role of a genetic control has been emphasized, but according to recent results obtained in a family segregation study, its participation seems limited. Prospective cohort studies of patients with previous myocardial infarction or angina pectoris have underlined the association between increased plasma PAI-1 levels and the risk of coronary events, but the predictive capacity of PAI-1 disappears after insulin resistance marker adjustments. Taken together these results support the notion that PAI-1 can be a link between obesity, insulin resistance and cardiovascular disease.Keywords
This publication has 26 references indexed in Scilit:
- Banting lecture 1988: Role of insulin resistance in human diseaseNutrition, 1997
- Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina PectorisCirculation, 1996
- Fibrinolysis and risk of coronary artery diseaseFibrinolysis, 1996
- Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart DiseaseNew England Journal of Medicine, 1996
- Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.Proceedings of the National Academy of Sciences, 1995
- The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM StudyThrombosis and Haemostasis, 1995
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosisDiabetologia, 1991
- Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjectsMetabolism, 1986